166 related articles for article (PubMed ID: 22270262)
1. Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy.
Lodde M; Lacombe L; Naselli A; Puppo P; Mian M; Fradet Y
World J Urol; 2013 Apr; 31(2):293-7. PubMed ID: 22270262
[TBL] [Abstract][Full Text] [Related]
2. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
3. Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy.
Yoo S; You D; Kim YS; Hong JH; Ahn H; Kim CS
Urol Int; 2017; 99(4):406-413. PubMed ID: 29020683
[TBL] [Abstract][Full Text] [Related]
4. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
[TBL] [Abstract][Full Text] [Related]
5. Small-volume lymph node involvement and biochemical recurrence after robot-assisted radical prostatectomy with extended lymph node dissection in prostate cancer.
Morizane S; Honda M; Shimizu R; Teraoka S; Nishikawa R; Tsounapi P; Kimura Y; Iwamoto H; Hikita K; Takenaka A
Int J Clin Oncol; 2020 Jul; 25(7):1398-1404. PubMed ID: 32333202
[TBL] [Abstract][Full Text] [Related]
6. Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy.
von Bodman C; Godoy G; Chade DC; Cronin A; Tafe LJ; Fine SW; Laudone V; Scardino PT; Eastham JA
J Urol; 2010 Jul; 184(1):143-8. PubMed ID: 20478587
[TBL] [Abstract][Full Text] [Related]
7. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.
Rigatti P; Suardi N; Briganti A; Da Pozzo LF; Tutolo M; Villa L; Gallina A; Capitanio U; Abdollah F; Scattoni V; Colombo R; Freschi M; Picchio M; Messa C; Guazzoni G; Montorsi F
Eur Urol; 2011 Nov; 60(5):935-43. PubMed ID: 21840116
[TBL] [Abstract][Full Text] [Related]
8. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era.
Gjertson CK; Asher KP; Sclar JD; Goluboff ET; Olsson CA; Benson MC; McKiernan JM
Urology; 2007 Oct; 70(4):723-7. PubMed ID: 17991544
[TBL] [Abstract][Full Text] [Related]
9. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
Messing EM; Manola J; Yao J; Kiernan M; Crawford D; Wilding G; di'SantAgnese PA; Trump D;
Lancet Oncol; 2006 Jun; 7(6):472-9. PubMed ID: 16750497
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of patients with lymph node metastasis treated with radical prostatectomy and adjuvant androgen deprivation therapy in a Chinese population: results from a cohort study.
Qin X; Han C; Zhang H; Dai B; Zhu Y; Shen Y; Zhu Y; Shi G; Ye D
World J Surg Oncol; 2015 May; 13():172. PubMed ID: 25943443
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
[TBL] [Abstract][Full Text] [Related]
13. Robotic-assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes.
Ledezma RA; Negron E; Razmaria AA; Dangle P; Eggener SE; Shalhav AL; Zagaja GP
World J Urol; 2015 Nov; 33(11):1689-94. PubMed ID: 25701128
[TBL] [Abstract][Full Text] [Related]
14. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
15. Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.
Marshall CH; Chen Y; Kuo C; Cullen J; Jiang J; Rosner I; Markowski M; McLeod DG; Trock BJ; Eisenberger MA
J Urol; 2021 Sep; 206(3):623-629. PubMed ID: 34003011
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
[TBL] [Abstract][Full Text] [Related]
17. Patterns of Clinical Recurrence of Node-positive Prostate Cancer and Impact on Long-term Survival.
Nini A; Gandaglia G; Fossati N; Suardi N; Cucchiara V; Dell'Oglio P; Cazzaniga W; Luzzago S; Montorsi F; Briganti A
Eur Urol; 2015 Nov; 68(5):777-84. PubMed ID: 25959166
[TBL] [Abstract][Full Text] [Related]
18. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
19. More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis.
Fossati N; Parker WP; Karnes RJ; Colicchia M; Bossi A; Seisen T; Di Muzio N; Cozzarini C; Noris Chiorda B; Fiorino C; Gandaglia G; Bartkowiak D; Wiegel T; Shariat S; Goldner G; Battaglia A; Joniau S; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A; Boorjian SA
Eur Urol; 2018 Aug; 74(2):134-137. PubMed ID: 29544737
[TBL] [Abstract][Full Text] [Related]
20. Surgical management of lymph-node-positive prostate cancer: improves symptomatic control.
Wiegand LR; Hernandez M; Pisters LL; Spiess PE
BJU Int; 2011 Apr; 107(8):1238-42. PubMed ID: 20880197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
